• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Healthcare

Relief From EpiPen's Stranglehold May Come From Rivals Before Politicians

Mylan's EpiPen continues to dominate the market as a one-time rival looks to come back.
By ANDERS KEITZ Sep 02, 2016 | 03:11 PM EDT
Stocks quotes in this article: MYL, SNY, IMMY, ADMP

Parents looking for relief from Mylan's (MYL) pricey EpiPen should not be holding their breath. The EpiPen will continue to dominate the epinephrine auto-injector market even as Democratic presidential candidate Hillary Clinton has unveiled a plan to address "excessive" increases in drug prices -- and that's because its one-time rival, Auvi-Q, remains off the market.

Auvi-Q was a novel epinephrine auto-injector that provided audio and visual cues for patients at risk for life-threatening allergic reactions. The product, created by twins Eric and Edward Edwards who formed pharmaceutical company Intelliject (which changed its name to kaléo in 2014), was considered superior to Mylan's EpiPen. According to a study published in The Journal of Allergy and Clinical Immunology, Auvi-Q was preferred over EpiPen on all study end points, which included method of instruction, preference to carry, device size and share.

Auvi-Q was in Sanofi's (SNY)  pipeline of products since 2013. But in 2015, Sanofi had to issue a nationwide recall of all Auvi-Q after the product had been found to potentially have inaccurate dosage delivery. Sanofi estimated an initial negative impact of approximately 100 million euros on the business's net income. Shortly after the recall, on Feb. 23, 2016, Sanofi announced that the license and development deal between Sanofi and kaléo would be terminated and returned Auvi-Q's rights to kaléo.

So with the product back in the hands of its developer, where is it?

"Kaléo is in the process of evaluating when and how to bring Auvi-Q back to individuals and families living with life-threatening allergies," said Mark Herzog, kaléo's Vice President of Corporate Affairs, via an email to Real Money. Herzog gave no timeline for the return to market, nor did he indicate what the price would be when Auvi-Q returns.

But given that people and families across America are clamoring for an alternative to the EpiPen, which carries a $600 price tag (or $300 for its generic two-pack carton), kaléo is missing out on a huge opportunity -- which it seems to acknowledge. "We are aware of the access challenges that patients have faced and we are monitoring the news media and conversation very closely," Herzog said.

Sanofi is also missing out, having just terminated a deal for EpiPen's more-preferred rival. Real Money's calls to Sanofi regarding the Auvi-Q product and whether the company would be interested in it again were not immediately returned.

But as kaléo works to return Auvi-Q to market, there are several dark horses trying to enter the epinephrine auto-injector race, such as Imprimis Pharmaceuticals (IMMY)  and Adamis Pharmaceuticals (ADMP) .

Mark Baum, CEO of Imprimis Pharmaceuticals (IMMY)  has plans to unveil a $100 alternative to the EpiPen. In an interview with CNNMoney on Aug. 30, Baum says his version of EpiPen would not cost much to make. He said that one milligram of epinephrine, which is three times more than what's in an EpiPen, costs just a couple of dollars. Furthermore, the auto injector is available at a cost between $3 and $7.

"Access should be the number one government policy, and right now, when you have monopolies that are artificially created, when there isn't competition prices go up and you have limited access for people," Baum said.

While Baum's $100 alternative has yet to hit the shelves and Auvi-Q's return remains in the works, parents will likely have to pay the market leader's price for the life-saving drug for now. Then again perhaps that will change come November, depending on who is sitting in the Oval Office.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are restricted from trading individual securities.

TAGS: Investing | U.S. Equity | Healthcare

More from Healthcare

Trade Carefully With Soaring Gritstone Oncology

Bruce Kamich
Jan 21, 2021 8:16 AM EST

The history we are concerned about is the past couple of weeks.

UnitedHealth Group Charts Appear Toppy Ahead of Earnings

Bruce Kamich
Jan 19, 2021 8:53 AM EST

The technical indicators of the health benefits concern are not sending strong signals at present.

Moderna Now Looks Like an Effective Long Trade With Few Side Effects

Bruce Kamich
Jan 14, 2021 12:06 PM EST

MRNA has corrected its big November rally and now looks ready to start a fresh advance, according to the charts.

Pacific Biosciences Reaches Our Price Target: Now What?

Bruce Kamich
Jan 13, 2021 12:19 PM EST

Let's check out the charts and technical indicators.

Emergent BioSolutions Is Looking Stronger

Bruce Kamich
Jan 12, 2021 10:37 AM EST

Here's an update on EBS shares.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:16 AM EST CHRIS VERSACE

    Worst Stocks to Buy for the Biden Presidency

    Biden's take on the minimum wage, likely moves on ...
  • 08:35 AM EST GARY BERMAN

    Thursday Morning Fibocall for 1/21/2021

    SPX (Long-Term View) The 1/20/21 NEW high @ 3859...
  • 11:38 AM EST CHRIS VERSACE

    Best Stocks to Buy for the Biden Presidency

    President-elect Biden's massive stimulus plan, int...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login